Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Medline Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medline Inc. (“Medline Inc.” or “the Company”) (NASDAQ: MDLN). Investors who purchased Medline Inc. securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Medline Inc. has violated federal securities laws.
Medline Inc. Investigation Details
On June 2, 2026, the U.S. Food and Drug Administration (“FDA”) published a warning letter detailing Medline’s “significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals” and stating that Medline “failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications.” On this news, Medline’s stock price fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026. Then, on August 5, 2026, Medline acknowledged in an earnings call that at least some of the remediation steps taken to address the issues in the FDA’s warning letter had “result[ed] in earnings loss”. Following this news, Medline’s stock price fell $5.38 per share, or 12.79%, to close at $36.67 per share on August 5, 2026.
What’s Next for Medline Inc. Investors?
If you are aware of any facts relating to this investigation or purchased Medline Inc. securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
MDLN — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”